Roger Yazbeck

Summary

Affiliation: University of South Australia
Country: Australia

Publications

  1. ncbi request reprint Indigenous Health: ACTION on Prevention - 50th annual Australian Society for Medical Research National Scientific Conference
    R Yazbeck
    School of Pharmacy and Medical Science, University of South Australia, Adelaide, South Australia, Australia
    Rural Remote Health 12:2256. 2012
  2. doi request reprint Biochemical and histological changes in the small intestine of mice with dextran sulfate sodium colitis
    Roger Yazbeck
    School of Biological Sciences, Flinders University, Adelaide, South Australia, Australia
    J Cell Physiol 226:3219-24. 2011
  3. ncbi request reprint Grape seed extract protects IEC-6 cells from chemotherapy-induced cytotoxicity and improves parameters of small intestinal mucositis in rats with experimentally-induced mucositis
    Ker Y Cheah
    Disciplines of Wine and Horticulture, School of Agriculture, Food and Wine, University of Adelaide, Adelaide, South Australia
    Cancer Biol Ther 8:382-90. 2009
  4. doi request reprint Dipeptidyl peptidase expression during experimental colitis in mice
    Roger Yazbeck
    School of Biological Sciences, Flinders University, Adelaide, South Australia, Australia
    Inflamm Bowel Dis 16:1340-51. 2010
  5. ncbi request reprint Dipeptidyl peptidases and inflammatory bowel disease
    Catherine A Abbott
    School of Biological Sciences, Flinders University, Adelaide, SA, Australia
    Adv Exp Med Biol 575:155-62. 2006
  6. ncbi request reprint Inhibiting dipeptidyl peptidase activity partially ameliorates colitis in mice
    Roger Yazbeck
    School of Biological Sciences, Flinders University, Adelaide, South Australia, Australia
    Front Biosci 13:6850-8. 2008
  7. ncbi request reprint The herbal extract, Iberogast, improves jejunal integrity in rats with 5-Fluorouracil (5-FU)-induced mucositis
    Tessa H Wright
    Centre for Paediatric and Adolescent Gastroenterology, Children, Youth and Women s Health Service, Adelaide, SA, Australia
    Cancer Biol Ther 8:923-9. 2009
  8. doi request reprint Growth factor based therapies and intestinal disease: is glucagon-like peptide-2 the new way forward?
    Roger Yazbeck
    School of Biological Sciences, Flinders University, Adelaide, South Australia, Australia
    Cytokine Growth Factor Rev 20:175-84. 2009
  9. ncbi request reprint Development and resolution of experimental colitis in mice with targeted deletion of dipeptidyl peptidase IV
    Mark S Geier
    Child Health Research Institute and Centre for Paediatric and Adolescent Gastroenterology, Women s and Children s Hospital, North Adelaide, South Australia, Australia
    J Cell Physiol 204:687-92. 2005
  10. doi request reprint Systematic review of agents for the management of gastrointestinal mucositis in cancer patients
    Rachel J Gibson
    School of Medical Sciences, University of Adelaide, North Terrace, Adelaide 5005, South Australia, Australia
    Support Care Cancer 21:313-26. 2013

Collaborators

Detail Information

Publications14

  1. ncbi request reprint Indigenous Health: ACTION on Prevention - 50th annual Australian Society for Medical Research National Scientific Conference
    R Yazbeck
    School of Pharmacy and Medical Science, University of South Australia, Adelaide, South Australia, Australia
    Rural Remote Health 12:2256. 2012
    ....
  2. doi request reprint Biochemical and histological changes in the small intestine of mice with dextran sulfate sodium colitis
    Roger Yazbeck
    School of Biological Sciences, Flinders University, Adelaide, South Australia, Australia
    J Cell Physiol 226:3219-24. 2011
    ..DPIV inhibitors are now a recognized therapy for type-II diabetes. The work presented here highlights the need to delineate any long-term effects of DPIV inhibitors on SI function, to further validate their safety and tolerability...
  3. ncbi request reprint Grape seed extract protects IEC-6 cells from chemotherapy-induced cytotoxicity and improves parameters of small intestinal mucositis in rats with experimentally-induced mucositis
    Ker Y Cheah
    Disciplines of Wine and Horticulture, School of Agriculture, Food and Wine, University of Adelaide, Adelaide, South Australia
    Cancer Biol Ther 8:382-90. 2009
    ..GSE may represent a promising prophylactic adjunct to conventional chemotherapy for preventing intestinal mucositis...
  4. doi request reprint Dipeptidyl peptidase expression during experimental colitis in mice
    Roger Yazbeck
    School of Biological Sciences, Flinders University, Adelaide, South Australia, Australia
    Inflamm Bowel Dis 16:1340-51. 2010
    ..We have previously demonstrated that inhibition of dipeptidyl peptidase (DP) activity partially attenuates dextran sulfate sodium (DSS) colitis in mice. The aim of this study was to further investigate the mechanisms of this protection...
  5. ncbi request reprint Dipeptidyl peptidases and inflammatory bowel disease
    Catherine A Abbott
    School of Biological Sciences, Flinders University, Adelaide, SA, Australia
    Adv Exp Med Biol 575:155-62. 2006
  6. ncbi request reprint Inhibiting dipeptidyl peptidase activity partially ameliorates colitis in mice
    Roger Yazbeck
    School of Biological Sciences, Flinders University, Adelaide, South Australia, Australia
    Front Biosci 13:6850-8. 2008
    ..Crypt hyperplasia (p<0.05) was observed in the saline group compared to P32/98 treatment at day 9. This preliminary study shows that novel inhibitors of DP activity may provide a new treatment strategy for IBD...
  7. ncbi request reprint The herbal extract, Iberogast, improves jejunal integrity in rats with 5-Fluorouracil (5-FU)-induced mucositis
    Tessa H Wright
    Centre for Paediatric and Adolescent Gastroenterology, Children, Youth and Women s Health Service, Adelaide, SA, Australia
    Cancer Biol Ther 8:923-9. 2009
    ..05). We conclude that although Iberogast partially improved the histopathological features of 5-FU induced mucositis, it conferred no significant protection as indicated by the assessed endpoints...
  8. doi request reprint Growth factor based therapies and intestinal disease: is glucagon-like peptide-2 the new way forward?
    Roger Yazbeck
    School of Biological Sciences, Flinders University, Adelaide, South Australia, Australia
    Cytokine Growth Factor Rev 20:175-84. 2009
    ..This review outlines evidence for the clinical application of GLP-2, its degradation resistant analogue, Teduglutide, and novel DPIV inhibitors in efficacy studies utilizing pre-clinical models of intestinal damage, in particular IBD...
  9. ncbi request reprint Development and resolution of experimental colitis in mice with targeted deletion of dipeptidyl peptidase IV
    Mark S Geier
    Child Health Research Institute and Centre for Paediatric and Adolescent Gastroenterology, Women s and Children s Hospital, North Adelaide, South Australia, Australia
    J Cell Physiol 204:687-92. 2005
    ..We conclude that loss of DPIV activity does not increase resistance to experimental colitis and hypothesize that other DPIV family members may also be involved in the cleavage of GLP-2...
  10. doi request reprint Systematic review of agents for the management of gastrointestinal mucositis in cancer patients
    Rachel J Gibson
    School of Medical Sciences, University of Adelaide, North Terrace, Adelaide 5005, South Australia, Australia
    Support Care Cancer 21:313-26. 2013
    ..The aim of this study was to review the available literature and define clinical practice guidelines for the use of agents for the prevention and treatment of gastrointestinal mucositis...
  11. ncbi request reprint The use of GLP-2 and related growth factors in intestinal diseases
    Roger Yazbeck
    Women s and Children s Hospital, Centre for Paediatric and Adolescent Gastroenterology, 72 King William Road, Adelaide, SA 5006, Australia
    Curr Opin Investig Drugs 11:440-6. 2010
    ....
  12. doi request reprint Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?
    Roger Yazbeck
    School of Biological Sciences, Flinders University, Adelaide, South Australia, Australia
    Trends Pharmacol Sci 30:600-7. 2009
    ..This review highlights recent insights into the applicability of DPP inhibitors as novel pharmacological agents for inflammatory disease...
  13. ncbi request reprint Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome
    Roger Yazbeck
    The University of Adelaide, Department of Medicine, Adelaide, South Australia 5005, Australia
    Curr Opin Mol Ther 12:798-809. 2010
    ..Teduglutide represents a novel, efficacious drug capable of increasing intestinal growth and improving intestinal function, and may change clinical management of intestinal disease and damage...
  14. doi request reprint Effects of Streptococcus thermophilus TH-4 in a rat model of doxorubicin-induced mucositis
    Hanru Wang
    School of Animal and Veterinary Sciences, The University of Adelaide, South Australia, Australia
    Scand J Gastroenterol 48:959-68. 2013
    ..However, its effects against other classes of chemotherapy drug have yet to be determined...